Ascendis Pharma Files 6-K Report
Ticker: ASND · Form: 6-K · Filed: Jan 15, 2025 · CIK: 1612042
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, registration
TL;DR
Ascendis Pharma filed a 6-K on Jan 15, 2025, for routine reporting.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on January 15, 2025, to report its activities for the month of January 2025. The filing is a report of a foreign private issuer and is incorporated by reference into several of its Form S-8 registration statements.
Why It Matters
This filing provides routine updates for Ascendis Pharma A/S as a foreign private issuer, informing investors about ongoing corporate activities.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that does not appear to contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
FAQ
What type of filing is this Form 6-K?
This is a Form 6-K Report of Foreign Private Issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the registrant for this filing?
The registrant is Ascendis Pharma A/S.
When was this Form 6-K filed?
This Form 6-K was filed on January 15, 2025.
What period does this report cover?
This report is for the month of January, 2025.
Into which registration statements is this report incorporated by reference?
This report is incorporated by reference into the registration statements on Form S-8 with Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, and 333-216883.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2025-01-15 16:39:59
Key Financial Figures
- $131.57 — y and has an exercise price equal to US $131.57 per share, the closing price of the Ame
Filing Documents
- d919382d6k.htm (6-K) — 12KB
- d919382dex11.htm (EX-1.1) — 1204KB
- g919382dsp174.jpg (GRAPHIC) — 3KB
- g919382dsp175.jpg (GRAPHIC) — 3KB
- g919382dsp177.jpg (GRAPHIC) — 3KB
- g919382dsp178.jpg (GRAPHIC) — 3KB
- g919382dsp179.jpg (GRAPHIC) — 3KB
- g919382dsp180.jpg (GRAPHIC) — 5KB
- g919382dsp_24a.jpg (GRAPHIC) — 4KB
- g919382dsp_25a.jpg (GRAPHIC) — 8KB
- g919382dsp_25b.jpg (GRAPHIC) — 3KB
- g919382dsp_26a.jpg (GRAPHIC) — 6KB
- g919382dsp_33a.jpg (GRAPHIC) — 4KB
- g919382dsp_33b.jpg (GRAPHIC) — 8KB
- g919382dsp_34a.jpg (GRAPHIC) — 3KB
- g919382dsp_34b.jpg (GRAPHIC) — 6KB
- g919382page43.jpg (GRAPHIC) — 4KB
- g919382page44a.jpg (GRAPHIC) — 8KB
- g919382page44b.jpg (GRAPHIC) — 3KB
- g919382page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-007078.txt ( ) — 1337KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: January 15, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer